| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4939130 | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(11 years ago) | |
| US8052987 | SANDOZ | Method of administering bisphosphonates |
Oct, 2023
(5 months ago) | |
| US7932241 | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
|
US7932241 (Pediatric) | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(4 years from now) | |
Reclast is owned by Sandoz.
Reclast contains Zoledronic Acid.
Reclast has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Reclast are:
- US4939130*PED
- US8052987
- US4939130
Reclast was authorised for market use on 16 April, 2007.
Reclast is available in injectable;intravenous dosage forms.
Reclast can be used as treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis, treatment of osteoporosis in postmenopausal women.
The generics of Reclast are possible to be released after 05 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-595) | May 29, 2012 |
| New Indication(I-581) | Dec 19, 2011 |
| New Indication(I-584) | Mar 15, 2012 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: INJECTABLE;INTRAVENOUS
RECLAST family patents
